Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase I/II, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

NCT01296555 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01296555
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01296555 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase I/II, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
March 16, 2011
Completion date
June 25, 2021
Enrollment
674 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin's lymphoma, solid cancers